Briacell Therapeutics Corp
BCTX9.150USD
+0.070+0.77%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
60.01MValor de mercado
PerdaP/L TTM
Mais detalhes de Briacell Therapeutics Corp Empresa
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Informações da empresa
Código da empresaBCTX
Nome da EmpresaBriacell Therapeutics Corp
Data de listagemOct 12, 2006
CEODr. William V. Williams, M.D.
Número de funcionários17
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 12
EndereçoSuite 300 - Bellevue Centre, 235 -15th Street
CidadeWEST VANCOUVER
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísCanada
Código postalV7T 2X1
Telefone16049211810
Sitehttps://briacell.com/
Código da empresaBCTX
Data de listagemOct 12, 2006
CEODr. William V. Williams, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.30K
+401.29%
Dr. Giuseppe Del Priore, M.D.
Dr. Giuseppe Del Priore, M.D.
Chief Medical Officer
Chief Medical Officer
18.84K
--
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
9.44K
+49573.68%
Dr. Miguel A. Lopez-Lago
Dr. Miguel A. Lopez-Lago
Chief Scientific Officer
Chief Scientific Officer
9.42K
--
Mr. Jamieson Bondarenko
Mr. Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
1.08K
+34.79%
Mr. Vaughn C. Embro-pantalony, CPA
Mr. Vaughn C. Embro-pantalony, CPA
Independent Director
Independent Director
119.00
+22.68%
Mr. Martin E. Schmieg, CPA
Mr. Martin E. Schmieg, CPA
Independent Director
Independent Director
--
--
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Independent Director
Independent Director
--
-100.00%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
--
-100.00%
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.30K
+401.29%
Dr. Giuseppe Del Priore, M.D.
Dr. Giuseppe Del Priore, M.D.
Chief Medical Officer
Chief Medical Officer
18.84K
--
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
9.44K
+49573.68%
Dr. Miguel A. Lopez-Lago
Dr. Miguel A. Lopez-Lago
Chief Scientific Officer
Chief Scientific Officer
9.42K
--
Mr. Jamieson Bondarenko
Mr. Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
1.08K
+34.79%
Mr. Vaughn C. Embro-pantalony, CPA
Mr. Vaughn C. Embro-pantalony, CPA
Independent Director
Independent Director
119.00
+22.68%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Heights Capital Management, Inc.
5.31%
Iroquois Capital Management, LLC
2.97%
Williams (William V)
1.87%
Del Priore (Giuseppe)
1.00%
L5 Capital Inc.
0.92%
Outro
87.92%
Investidores
Investidores
Proporção
Heights Capital Management, Inc.
5.31%
Iroquois Capital Management, LLC
2.97%
Williams (William V)
1.87%
Del Priore (Giuseppe)
1.00%
L5 Capital Inc.
0.92%
Outro
87.92%
Tipos de investidores
Investidores
Proporção
Investment Advisor
5.39%
Individual Investor
3.94%
Hedge Fund
2.97%
Investment Advisor/Hedge Fund
1.26%
Corporation
1.21%
Research Firm
0.03%
Outro
85.19%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
65
831.24K
7.95%
-645.60K
2025Q1
68
476.26K
7.27%
-513.92K
2024Q4
65
403.53K
10.88%
-198.25K
2024Q3
64
441.30K
30.40%
+131.88K
2024Q2
63
437.48K
31.09%
+121.43K
2024Q1
62
332.09K
21.52%
-17.16K
2023Q4
67
402.86K
34.69%
+35.57K
2023Q3
74
369.20K
35.11%
-158.11K
2023Q2
84
434.95K
41.59%
-338.84K
2023Q1
83
423.04K
40.96%
-355.97K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Heights Capital Management, Inc.
489.20K
7.46%
+489.20K
--
Apr 24, 2025
Williams (William V)
10.81K
0.16%
+222.00
+2.10%
Dec 09, 2024
L5 Capital Inc.
174.03K
2.65%
+4.50K
+2.65%
Dec 10, 2024
Lynwood Capital Management Inc.
106.52K
1.62%
+1.14K
+1.08%
Mar 31, 2024
Levin (Gadi)
187.00
0%
--
--
Dec 09, 2024
3I Management LLC
91.69K
1.4%
-277.31K
-75.15%
Mar 31, 2025
Copia Fund (Cayman) LP
54.56K
0.83%
+54.56K
--
Dec 29, 2023
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
Data
Tipo
Proporção
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
